Intractable & Rare Diseases Research is a pioneering journal dedicated to advancing the understanding and treatment of rare and intractable diseases. Published by INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT in Japan, this esteemed journal serves as a critical platform for researchers, clinicians, and healthcare professionals to share groundbreaking findings and developments in the field. With its established Scopus ranking of #238 out of 636 in the General Medicine category, placing it in the 62nd percentile, and its classification in the Q3 quartile for 2023, it is recognized as a significant contributor to the literature on rare diseases. Operating without an open-access model, the journal ensures high-quality content cultivated through rigorous peer-review processes. Through its scope spanning from 2012 to 2024, the journal aspires to bridge gaps in knowledge and foster collaboration among interdisciplinary researchers, ultimately aiming to improve patient outcomes and enhance public health concerning these challenging conditions.

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.

JCI Insight, published by the American Society for Clinical Investigation, stands as a vital resource in the field of medicine, having achieved a prestigious Q1 rating in the 2023 category for miscellaneous medicine. With an impressive Scopus rank of 27 out of 636, placing it in the 95th percentile, this journal emphasizes the dissemination of high-quality, peer-reviewed research that pushes the boundaries of clinical and translational science. Since becoming an Open Access journal in 2020, JCI Insight has expanded its reach, providing researchers, professionals, and students around the globe with unfettered access to groundbreaking studies and reviews. The journal focuses on a wide spectrum of topics relevant to the medical community, making it an essential platform for sharing innovative findings and fostering collaboration among scientists dedicated to transforming health outcomes. Based in Ann Arbor, Michigan, JCI Insight continues to inspire advancements in medical research, contributing significantly to the ongoing dialogue in the ever-evolving healthcare landscape.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

The Egyptian Rheumatologist is a peer-reviewed Open Access journal dedicated to advancing the field of rheumatology. Published by Elsevier since 2011, the journal aims to disseminate high-quality research, clinical innovations, and reviews that cover a wide range of topics related to autoimmune diseases, arthritis, and musculoskeletal disorders. With an ISSN of 1110-1164 and an E-ISSN of 2090-2433, it has achieved a respectable rank of #50 out of 73 in the medicine/rheumatology category according to Scopus, positioning it in the 32nd percentile among its peers. Operating from its base in Amsterdam, Netherlands, the journal provides an accessible platform for researchers, professionals, and students, encouraging a collaborative exchange of cutting-edge knowledge that is essential for the ongoing developments in rheumatologic care and research. The Open Access model ensures that critical findings and advancements are available to a global audience, fostering further research and education within this vital field.

The Scandinavian Cardiovascular Journal, published by Taylor & Francis Ltd, is a distinguished peer-reviewed journal aimed at advancing the field of cardiology and cardiovascular medicine. With an impressive history dating back to 1967 and a forward-looking perspective until 2024, it has consistently contributed valuable research and insights, making it essential reading for anyone involved in cardiovascular healthcare. The journal holds a strong position in the academic community, reflected in its Q2 rating in both Cardiology and Cardiovascular Medicine, and a similar classification in the broader field of Medicine as of 2023. It is indexed in multiple databases, with a Scopus rank of #178 out of 387 in its category, placing it in the 54th percentile. The journal provides open access options, promoting wider dissemination of knowledge while supporting both researchers and practitioners dedicated to improving cardiovascular health. Its focus on high-quality, impactful research makes it an invaluable resource for professionals and students alike, keen to stay at the forefront of cardiology advancements.

CLINICAL SCIENCE, published by PORTLAND PRESS LTD, is a prestigious journal with an established history that dates back to 1946. Renowned for its rigorous peer-reviewed articles, the journal is dedicated to advancing knowledge in the field of medicine, particularly in the nuances of clinical science and translational research. With an impressive Q1 ranking in the **Medicine (miscellaneous)** category and a Scopus rank of #32 out of 636 in general medicine, it is firmly positioned in the top 5% percentile of its field, making it an essential resource for researchers, practitioners, and students aiming to stay at the forefront of the discipline. Although the journal operates on a traditional subscription model, its influence and accessibility ensure that critical findings and innovative methodologies reach a wide audience, fostering collaboration and progress within the global medical community. The journal seeks to publish groundbreaking studies, critical reviews, and insights that can translate into improved clinical practices, thus reinforcing its mission to enhance patient care and medical knowledge.

Sarcoidosis Vascularitis and Diffuse Lung Diseases is a prestigious academic journal published by Mattioli 1885, focusing on the interdisciplinary study of sarcoidosis, vasculitis, and various diffuse lung diseases. Since its inception in 1996, this journal has been pivotal in disseminating vital research findings, clinical experiences, and comprehensive reviews related to these complex conditions, supporting health professionals and researchers in advancing their understanding and treatment approaches. With a convergence period extending to 2024, the journal has gained recognition in multiple categories, including Q4 in Immunology and Allergy, and Q3 rankings in Internal Medicine, Medicine (Miscellaneous), and Pulmonary and Respiratory Medicine, reflecting its commitment to high-quality and impactful studies. Although currently not offering open access, its contributions are indispensable for the academic community, making it a vital resource for those dedicated to improving patient outcomes and fostering knowledge in the field.

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

Journal of Inflammation-London, published by BMC, is a premier open access journal dedicated to advancing the understanding of inflammation, a critical process underlying numerous diseases including autoimmune disorders, cancer, and cardiovascular conditions. With its inception in 2004, the journal has consistently delivered high-quality research that bridges basic science and clinical applications, maintaining a significant place in the academic community. It holds impressive rankings within the Q2 category for both Cell Biology and Clinical Biochemistry, reflecting its impactful contributions to these fields, where it ranks in the 73rd and 64th percentiles respectively. The journal is committed to open access principles, ensuring that all published articles are freely available to researchers, practitioners, and the global community, thereby fostering collaboration and innovation. Located in the United Kingdom, the journal continues to attract submissions from prominent researchers and institutions worldwide, solidifying its status as an essential resource for the latest developments in inflammation research.